



FOR IMMEDIATE RELEASE

June 4, 2011

Breckenridge Announces Approval of Letrozole Tablets

Boca Raton, Florida, June 04, 2011– Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Letrozole 2.5 mg Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA) for this product, which is being supplied under a licensing agreement. Letrozole Tablets are AB rated to Femara®, a \$700 million dollar oncology drug marketed by Novartis.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders. www.bpirx.com

For Further Information, please contact:

Breckenridge Pharmaceutical

Larry Lapila, Executive Vice President

TEL: 860-828-8140 FAX: 860-828-8142

e-Mail: llapila@bpirx.com